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Abstract
Background: Early Alzheimer’s disease (AD) diagnosis is vital for development of disease-modifying therapies. Prior
to significant brain tissue atrophy, several microstructural changes take place as a result of Alzheimer’s pathology. These
include deposition of amyloid, tau and iron, as well as altered water homeostasis in tissue and some cell death. T2
relaxation time, a quantitative MRI measure, is sensitive to these changes and may be a useful non-invasive, early
marker of tissue integrity which could predict conversion to dementia. We propose that different microstructural
changes affect T2 in opposing ways, such that average ‘midpoint’ measures of T2 are less sensitive than measuring
distribution width (heterogeneity). T2 heterogeneity in the brain may present a sensitive early marker of AD pathology.
Methods: In this cohort study, we tested 97 healthy older controls, 49 people with mild cognitive impairment (MCI)
and 10 with a clinical diagnosis of AD. All participants underwent structural MRI including a multi-echo sequence for
quantitative T2 assessment. Cognitive change over 1 year was assessed in 20 participants with MCI. T2 distributions
were modelled in the hippocampus and thalamus using log-logistic distribution giving measures of log-median value
(midpoint; T2μ) and distribution width (heterogeneity; T2σ).
Results: We show an increase in T2 heterogeneity (T2σ; p < .0001) in MCI compared to healthy controls, which was not
seen with midpoint (T2μ; p = .149) in the hippocampus and thalamus. Hippocampal T2 heterogeneity predicted
cognitive decline over 1 year in MCI participants (p = .018), but midpoint (p = .132) and volume (p = .315) did not. Age
affects T2, but the effects described here are significant even after correcting for age.
Conclusions: We show that T2 heterogeneity can identify subtle changes in microstructural integrity of brain tissue in
MCI and predict cognitive decline over a year. We describe a new model that considers the competing effects of factors
that both increase and decrease T2. These two opposing forces suggest that previous conclusions based on T2 midpoint
may have obscured the true potential of T2 as a marker of subtle neuropathology. We propose that T2 heterogeneity
reflects microstructural integrity with potential to be a widely used early biomarker of conditions such as AD.
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Introduction
Alzheimer’s disease treatments and therapies that stop
or slow down neuropathology will be most effective if
administered as early as possible; before significant neu-
rodegeneration has occurred. Accurate early Alzheimer’s
disease diagnosis is vital to identify appropriate clinical
trial study groups of ‘at-risk’ individuals to expedite
development of new compounds [1, 2] and to target
disease-modifying treatments when available.
Structural and quantitative MRI show promise in their
ability to identify changes in the brain that indicate early
Alzheimer’s pathology. Measuring the volume of the
hippocampus and entorhinal cortex has been shown to
predict progression of mild cognitive impairment (MCI)
to Alzheimer’s disease [3–10]. Detectable change in vol-
ume is indicative of significant tissue loss, which is likely
to be irreversible. As treatment with disease-modifying
therapies would be optimal before such significant
macrostructural change, we ask whether MRI could be
used to identify microstructural changes that occur earl-
ier in the disease-course, before significant volume loss.
Prior to significant loss of tissue volume, several micro-
structural changes take place as a result of Alzheimer’s dis-
ease pathology—(i) oligomers and plaques of β-amyloid
(Aβ) and neurofibrillary tangles (NFTs) build up around
the medial temporal lobe (MTL) and the thalamus [11–14],
(ii) iron is elevated in the brains of people with MCI and
Alzheimer’s disease [15] and (iii) even small amounts of ne-
crosis leading to breakdown of cell membranes and oedema
will increase the motility of water within a given region.
Increase in water motility is not necessarily specific
to Alzheimer’s disease and can occur in healthy age-
ing [16–18]. Accurately measuring such microstruc-
tural changes may allow identification of tissue that is
at risk of degradation or has reduced functionality
compared to a previous state.
T2 relaxometry is an MRI approach that may be able
to report microstructural tissue integrity. Relaxation
time is a measure, detectable by MRI, that describes the
time taken for protons to return to a state of equilibrium
following electromagnetic excitation. Specifically, T2 re-
laxation describes the transverse component of magnet-
isation. T2 relaxation time of biological tissue varies
depending on its physical properties and its surrounding
environment. It is primarily driven by water content and
mobility and the presence of macromolecular structures
and paramagnetic materials, e.g. iron [19–23]. For example,
pure water will have a very long relaxation time, whereas in
fatty substances, T2 will decay much quicker. T2 is there-
fore sensitive to microscopic and physico-chemical tissue
properties that can change as a result of pathology. Previous
research has shown that T2 relaxometry is independent of,
and can provide distinct microstructural information to,
diffusion tensor imaging metrics [24, 25].
Given that quantitative T2 can be easily measured on
routine MRI scans, adding just a couple of minutes to
standard T2-weighted structural scanning times, it has been
previously explored as an early marker of Alzheimer’s dis-
ease pathology. However, previous studies on the effect of
Alzheimer’s pathology on T2 in the human brain have
yielded varied and sometimes contradictory results. Most
studies describe a prolonged T2 in the hippocampus of
those with Alzheimer’s disease [26–30], whereas others find
the opposite [31, 32] or no change at all [33] (see
Tang et al. [34] for a comprehensive review). In two
studies [26, 28], change in thalamic T2 was not asso-
ciated with Alzheimer’s pathology or cognitive impair-
ment, but T2 increased with age [28]. In another
study, Dawe et al. [30] found that Alzheimer’s path-
ology was associated with decreased T2 within the
thalamus.
These inconsistencies in human literature are not fully
reflected in studies of transgenic rodent models of
Alzheimer’s disease, which consistently show a decrease
in hippocampal T2 [34]. Inconsistencies within the hu-
man literature and between human and animal studies
could be a consequence of the multiple pathological pro-
cesses occurring in the human brain that have opposing
effects, either shortening or lengthening T2. In contrast,
mouse models are usually dominated by a single patho-
logical process such as amyloid deposition.
Increased water content, such as that caused by in-
creased cerebrospinal fluid (CSF), oedema or cell mem-
brane damage, will prolong T2 [28]. Conversely, increase
in iron [22] or in macromolecule-to-water ratio due to
accumulation of high density protein aggregates, such as
Aβ, shorten T2 [35]. Even in early stages of the patho-
logical progression of Alzheimer’s disease within the
brain, factors which cause T2 to either increase or de-
crease are both occurring in early-affected regions such
as the hippocampus and the thalamus [11, 14, 36, 37].
Either effect may be more or less dominant in clusters
throughout these regions. Averaging across the entire re-
gion could therefore yield, on average, a net change in
T2 of zero. A change in the average value of T2 would
only come about if T2-shortening factors dominate over
T2-prolonging factors or vice-versa, which may not be
the case in the earliest stages of the disease. Rather, an
increased width of the distribution of T2 (T2 heterogen-
eity) may better reflect subtle changes in microstructural
integrity such as those present in the early stages of
Alzheimer’s disease.
T2 heterogeneity as a marker of tissue integrity is a
novel measure with only two known previous studies of
its utility. One demonstrates that T2 heterogeneity is a
useful measure in accurately determining stroke onset
time in an animal model [38]. The other presented pilot
data from our group, concluding that T2 heterogeneity
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can improve accuracy in distinguishing between healthy
controls, those with MCI and Alzheimer’s disease pa-
tients, and was a more promising measure than volume-
try or diffusion tensor imaging [25].
In this study, we aimed to assess the use of the width
of the distribution of T2 as a marker of within-
individual tissue heterogeneity and microstructural in-
tegrity. We measure T2 heterogeneity in a group of
people with MCI. Studies report a variable annual con-
version rate of MCI to AD (mostly ranging from 10 to
15% for studies in clinical settings [39, 40]). We
hypothesised that MCI patients with the greatest T2 het-
erogeneity would have the greatest risk of incipient de-
mentia and therefore experience the greatest cognitive
decline over a year [39, 40]. To be clear, we expect the
distribution width to increase on a patient-by-patient
basis. We are not discussing heterogeneity across the
MCI group, which would be explained by the variety of
MCI aetiologies between individuals.
We expand previous work by describing a model of
T2 dynamics through the course of Alzheimer’s disease,
in comparison to healthy ageing, with a view to creating
a practical biomarker which may identify neuropathol-
ogy prior to significant tissue atrophy. We also report
volumetry data, as this is the current standard for asses-
sing structural change in MCI and AD.
Methods
The analyses in this paper combine data from two pro-
spective longitudinal studies similar in cohort demo-
graphics and study design. No participants took part in
both studies. Both studies are detailed in the following
section. Where data collected are not identical between
cohorts, we have normalised equivalent metrics within
cohort and combined data after normalisation.
Participants
Participants fulfilling the Petersen criteria [41] for diag-
nosis of MCI were recruited to both studies (study 1:
n = 30; study 2: n = 29). Healthy older people (HC) with
no history of memory problems or significant neuro-
logical disorders were recruited as controls to each study
(study 1: n = 61; study 2: n = 56). All healthy controls
had Montreal Cognitive Assessment (MoCA) > 26 (study
1) or Addenbrookes Cognitive Examination 3 (ACE-III)
> 88 (study 2). Seven participants originally recruited as
healthy controls in study 1 were found to have MoCA
scores of < 26, so they were reclassified as MCI (given
the high sensitivity and specificity of the MoCA for de-
tecting MCI at this threshold; 90% and 100%, respect-
ively [42]). Study 1 also included 10 patients with
diagnoses of Alzheimer’s disease (AD) who retained cap-
acity to consent. AD diagnoses were made according to
standard clinical criteria [43]. These sample sizes are in-
line with similar studies on brain structure abnormalities
in MCI and Alzheimer’s disease and are sufficient to ob-
serve significant differences in hippocampal volume. All
participants underwent a battery of neuropsychological
tests specific to each study, the details of which are de-
scribed in supplementary information.
Subjects for both studies were recruited from local GP
surgeries and memory clinics in the Bristol area (having
received MCI diagnoses or reported memory problems),
Join Dementia Research, Avon and Wiltshire Mental
Health Partnership’s Everyone Included system, an in-
house database of volunteers, replies to poster adverts or
through word of mouth. All patients provided informed
written consent prior to testing as according to the
Declaration of Helsinki. Ethical approval was given by
Frenchay NHS Research Ethics Committee.
The current analyses included all participants who had
volumetry and T2 relaxometry data for both hippocam-
pal subfields and thalamus, study 1 n = 90 (50 HC, 30
MCI, 10 AD), study 2 n = 66 (47 HC, 19 MCI). See
Table 1 for demographic details (Supplementary Tables 1
and 2 show demographic, neuropsychology and MRI
data for each study cohort separately).
A total of 20 MCI participants were followed-up after
1 year (10 from each study). Cognitive function was
tested at baseline and follow-up using the MoCA in
study 1 and the ACE-III in study 2. We assessed cogni-
tive decline as an overall change in this cognitive test
score over the year follow-up period. Although some
MCI patients may have converted to dementia over the
year, conversion to dementia was never a formal out-
come of this study. The reason for this is that we re-
cruited from a range of sites with highly variable clinical
follow-up periods for MCI patients—indeed, some sites
discharge MCI patients without a planned follow-up.
This led to our decision to use our own measure of cog-
nitive change as the outcome of interest in this study.
Imaging parameters
Scans for both studies were acquired at CRICBristol,
University of Bristol, UK, on the same Siemens Magne-
tom Skyra 3T system equipped with a parallel transmit
body coil and a 32-channel head receiver array coil. The
two studies used similar, but slightly different scanning
protocols.
Study 1
This protocol has been previously described by Knight
et al. [25]. The imaging protocol included a 3D T1-
weighted whole-brain magnetization prepared rapid ac-
quisition gradient-echo (MPRAGE) and 2D multi-
contrast multi-spin-echo (CPMG).
MPRAGE: Coronal, whole-brain, repetition time (TR)
2200 ms, echo time (TE) 2.42 ms, inversion time (TI)
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900 ms, flip angle 9°, acquired resolution 0.68 × 0.68 ×
1.60 mm, acquired matrix size 152 × 320 × 144, recon-
structed resolution 0.34 × 0.34 × 1.60 mm (after twofold
interpolation in-plane by zero-filling in k-space), recon-
structed matrix size 540 × 640 × 144, GRAPPA factor 2.
Acquisition time: 5:25 min.
CPMG: Coronal, TR 4500 ms, TE 12ms, number of
echoes 10, echo spacing 12 ms, acquired resolution
0.68 × 0.68 × 1.7 mm inclusive of 15% slice gap, acquired
matrix size 152 × 320, 34 slices, interleaved slice order,
reconstructed resolution 0.34 × 0.34 × 1.7 mm (after two-
fold interpolation in-plane by zero-filling in k-space, and
inclusive of 15% slice gap), reconstructed matrix size
540 × 640, 34 slices, GRAPPA factor 2. Acquisition time:
11:07 min.
Study 2
The imaging protocol included a 3D T1-weighted
whole-brain MPRAGE and 2D multi-contrast turbo
spin-echo (TSE).
MPRAGE: Sagittal, whole-brain, TR 2200ms, TE 2.28
ms, TI 900 ms, flip angle 9°, FOV 220 × 220 × 179 mm,
acquired resolution 0.86 × 0.86 × 0.86 mm, acquired
matrix size 256 × 256 × 208. Acquisition time: 5:07 min.
Multi-contrast TSE: Coronal, TR 7500ms, number of
echoes: 3, TE 9.1, 72 and 136 ms, acquired resolution
0.69 × 0.69 × 1.5 mm, reconstructed resolution 0.34 ×
0.34 × 1.5 mm (after 2-fold interpolation in-plane by
zero-filling in k-space, and inclusive of 15% slice gap),
GRAPPA factor 2, FOV 220 × 220 × 34, acquired matrix
size 270 × 320 × 58. Acquisition time: 5:09 min.
CPMG and TSE scans were not ‘whole-brain’, their
coverage only extending approx. 1 cm beyond anterior
and posterior ends of the hippocampus. These scans
were tilted such that the hippocampal body lay perpen-
dicular to the slice acquisition plane. These scans also
included the entirety of thalamus.
The two distinct methods of measuring T2 (CPMG vs
TSE) will give inherently different values for T2 midpoint
and heterogeneity between studies (see supplementary
information). Relationships to variables such as age and
cognitive score should be similar, given they are sensitive
to the same tissue properties.
Imaging analyses
All analyses were performed at CRICBristol in a Linux
cluster environment. All analyses were carried out in
single-subject native space.
CPMG and TSE scans were brain-extracted using
FSL’s bet2 on the first echo in the series [44]. All ex-
tracted images were visually inspected for quality and re-
run with different fractional intensity thresholds or
gradient parameters where necessary. Fractional inten-
sity threshold was typically set between 0.2–0.3.
MPRAGE images were brain-extracted using vbm8bet
(in-house script) and bias-field-corrected using FSL
FAST [45]. T2 maps were created in MATLAB from
multi-echo sequences by fitting logarithmic-space
mono-exponential decay functions to each voxel series
(overall summary of T2 calculation is shown in Knight
et al. [25]). The first echo of CPMG was always ex-
cluded. A sum-of-echoes image was created in order to
have one structural image representing the entire multi-
echo sequence. This image was used for segmentation.
Hippocampus was automatically masked using the
Automatic Segmentation of Hippocampal Subfields
(ASHS) software package [46] (version: rev103, dated 12
June 2014; UPENN memory centre atlas dated 16 April
2014). CA1, CA2, CA3, dentate gyrus, subiculum and
miscellaneous were combined to form a total hippocam-
pus mask. This was overlaid onto T2 maps, giving a
value of T2 for each voxel of hippocampus.
Whole thalamus masks were created using Freesurfer
v6.0, using MPRAGE scans as input images [47]. After
extraction from the Freesurfer segmentation image and
registration to T2-space (TSE or CPMG) using FSL’s
FLIRT, thalamus masks were then overlaid onto T2
maps, and descriptive statistics were calculated, similarly
to hippocampus. These automated masking programmes
have demonstrated high accuracy whilst minimising sub-
jective rater bias, without the need for group blinding.
Modelling T2 heterogeneity
Distribution histograms were capped at 30 ms and 200
ms, as values outside these regions are unphysiological
in brain tissue at 3T. The free-to-download MATLAB
function ‘fitmethis’ [48] was used to fit 18 different
Table 1 Participant demographics
Group
HC MCI AD Total
N (male to female) 97 (46:51) 49 (27:22) 10 (2:8) 156 (75:81)
Age (years) 69.3 ± 8.58 72.2 ± 9.03 77.9 ± 9.94 70.7 ± 9.05
YOE 15.8 ± 3.16 14.2 ± 2.81 13.1 ± 2.60 15.1 ± 3.13
Cognitive score (normalised to HC) 0.00 ± 1.00 − 4.08 ± 2.09 − 8.50 ± 3.15 − 1.83 ± 3.02
Data show mean ± standard deviation, combined for studies 1 and 2. Cognitive score is calculated as a Z score relative to the healthy control group of each study,
separately, as different cognitive tests were used (study 1: MoCA; study 2: ACE-III). For this reason, the HC group by definition has a mean ± SD of 0 ± 1. HC healthy
control, MCI mild cognitive impairment, AD Alzheimer’s disease, YOE years of education
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distribution functions (see supplementary information)
to left and right hemisphere ROIs individually, using
maximum likelihood estimation. Akaike Information
Criteria (AIC) was calculated for each distribution type.
The best fitting model was determined by the lowest
AIC. The most frequent best-fitting model was recorded
for the hippocampus and thalamus, and subsequent sta-
tistics calculated therefrom.
Statistical analysis
ICV-corrected volumes, T2 metrics and cognitive scores
were converted into Z scores for each study separately
and pooled, with healthy controls of each study as a ref-
erence population. MANCOVA results comparing the
two cohorts before and after this normalisation can be
found in Supplementary Tables 3 and 4. Model parame-
ters of T2 distributions were compared between groups
using ANCOVA, with age as a covariate. Years of educa-
tion and study (1 or 2) were included as the covariates
in all models but did not significantly contribute to the
model in any case. We also ran models using gender as
a covariate, the results of which are shown in supple-
mentary information (Supplementary Table 5), but the
overall pattern of results was unchanged. Reported
models correct for age but not years of education, study,
or gender. Homogeneity of variances was tested using
Levene’s test, which was not significant for any test.
Graphs show estimated marginal means from this ana-
lysis. Post-hoc pairwise comparisons were carried out
using sidak correction for multiple comparisons (cor-
rected p values are shown as ‘psidak’). Ability of volume
and T2 to predict cognitive decline was assessed using
linear regression, with follow-up cognition as the
dependent variable and baseline cognition and age as
covariates:
Follow − up Cognition ¼ βintercept þ βage Ageð Þ
þ βBLCog BaselineCognitionð Þ
þ βVolume=T2 Volume=T2ð Þ
þ error
Gender and study were also explored as covariates in
these linear regression models; however, in no model
were they significant predictors. Z scores for the latter
analysis were calculated relative to each study’s MCI
population only.
Linear regressions were used to assess the strength of
the relationship between age and T2 statistics in healthy
controls. All reported p values are two-tailed. Balance
tests were not carried out on demographic for reasons
detailed by Mutz et al. [49].
Data handling and storage was carried out using
MathWorks MATLAB 2015a (with statistics and ma-
chine learning toolbox) and Microsoft Excel 2016.
Statistical analysis was performed in IBM SPSS Statistics
24. Graphs were produced using GraphPad Prism v7.
Results
Demographic details for the entire cohort can be found
in Table 1. Separated demographic information for study
1 and study 2 can be found in Supplementary Tables 1
and 2, respectively, including specific cognitive test
scores for each group.
Model fitting to describe T2 distribution characteristics
T2 distributions in the hippocampus and thalamus (Fig.
1) were best described in the majority of cases by a log-
logistic distribution function (as determined by the low-
est AIC). Log-logistic distribution is defined as:





1þ exp zð Þ½ 2 ;where z ¼
log xð Þ − μ
σ
where μ and σ denote the log-median value (midpoint)
and distribution shape (heterogeneity), respectively.
Values for hippocampus and thalamus volume and T2
model parameters can be found in Supplementary Ta-
bles 3 and 4.
T2 heterogeneity, but not midpoint, differentiates healthy
older adults from those with MCI
T2 midpoint (μ)
There was no significant difference between HC, MCI
and AD groups (F(2, 152) = 1.61, p = .204; Fig. 2a) on T2
midpoint in the hippocampus. Although T2 midpoint
was higher in the AD group than other groups, this ef-
fect was not statistically significant compared to either
healthy controls (pSidak = .283) or the MCI group (pSi-
dak = .211). There was no significant difference between
healthy control and MCI groups (pSidak = .971).
We found a significant effect of group on T2 midpoint
in the thalamus (F(2, 152) = 3.10, p = .048; Fig. 2a). Post
hoc analyses revealed that this was driven by an increase
in T2 in the AD group (HC vs AD: pSidak = .042; MCI vs
AD: pSidak = .073). As in the hippocampus, there was no
significant difference between healthy controls and the
MCI group (pSidak = .989).
T2 heterogeneity (σ)
There was a significant effect of group on hippocampal
T2 heterogeneity (F(2, 152) = 9.76, p = .0001; Fig. 2b).
Pairwise comparisons revealed a significantly wider dis-
tribution in the MCI group compared to healthy con-
trols (pSidak < .0001). There was no significant further
change from MCI to AD (pSidak = .913), nor was there a
significant difference between healthy controls and the
AD group (pSidak = .273).
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There was a significant difference in thalamic T2σ be-
tween groups (F(2, 152) = 5.90, p = .003; Fig. 2b). Post
hoc pairwise comparisons revealed a significantly in-
creased T2σ in the MCI group compared to HCs (pSi-
dak = .002). In line with findings in the hippocampus, we
observed no significant difference between MCI and AD
groups (pSidak = .813) or between healthy controls and
the AD group (pSidak = .710).
Volume
We found a significant effect of group on volume (F(2,
152) = 14.8, p < .0001; Fig. 2c). Pairwise comparisons re-
vealed a significantly smaller volume in the MCI group
compared to healthy controls (pSidak < .0001), as well as a
significant difference between HC and AD groups (pSidak =
.014). There was no significant further increase from MCI
to AD (pSidak = .994).
There was a significant difference in thalamic volume
between groups (F(2, 152) = 3.41, p = .036; Fig. 2c).
Post hoc pairwise comparisons revealed a significantly
smaller volume in the MCI group compared to HCs
(pSidak = .032).
T2 heterogeneity predicts cognitive decline in mild
cognitive impairment
Hippocampal T2 heterogeneity significantly predicted
follow-up cognitive score, after accounting for baseline
cognitive score and age (R2 = .387, F(3, 16)=3.37, p =
.045; Fig. 3b). T2 heterogeneity was the sole significant
individual predictor in this model (βT2σ = −.601, pT2σ =
Fig. 1 Hippocampal T2 relaxation time histograms for example participants. Left: Healthy control, 69-year-old female (μ = 4.68, σ = .112). Right:
MCI, 87-year-old male (μ = 4.71; σ = .135). Left hippocampus is shown in both examples. Red lines on each graph represent log-logistic
distribution curves fitted to each participant’s data
Fig. 2 Group comparisons for structural measures in hippocampus and thalamus. Comparisons are shown for a T2 midpoint (μ), b T2
heterogeneity (σ) and c ICV-corrected volume. Values shown are estimated marginal means after correcting for the effect of age. Error bars show
marginal means ± standard error. Asterisks represent Sidak pairwise comparisons p values (*p < .05; **p < .01; ****p < .0001)
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.018). Cognitive change over time was not predicted by
this method by either hippocampal T2μ (R2 = .241, F(3,
16)=1.69, p = .209; βT2μ = −.377, pT2μ = .132; Fig. 3a) or
hippocampal volume (R2 = .177, F(3, 16)=1.15, p = .361;
βvol = .263, pvol = .315; Fig. 3c).
Effects of age on T2 relaxometry and volume in
individuals with normal cognition
T2 midpoint (μ)
There was no statistically significant relationship be-
tween age and hippocampal T2 midpoint (T2μ, R2 =
.012, p = .289, n = 97; Fig. 4a) in cognitively normal indi-
viduals. In the thalamus, age was a strong positive pre-
dictor of T2μ (R2 = .320, p < .0001, n = 97; Fig. 4b).
T2 heterogeneity (σ)
Age was a significant positive predictor of T2 heterogen-
eity in the hippocampus (T2σ, R2 = .122, p = .0004;
Fig. 4c) and thalamus (R2 = .127, p = .0003; Fig. 4d) in
cognitively normal individuals.
Volume
Age was a significant positive predictor of volume in the
hippocampus (R2 = .106, p = .001; Fig. 4e) and thalamus
(R2 = .134, p = .0002; Fig. 4e) in cognitively normal
individuals.
Discussion
We show that the width of the distribution of T2 in the
hippocampus and the thalamus differentiates healthy
older adults from those with mild cognitive impairment,
while the T2 midpoint does not. Heterogeneity of T2
may therefore be a marker of structural integrity, which
has potential detect early signs of Alzheimer’s disease
pathology. Although ageing affects T2, even after con-
trolling for age, T2 heterogeneity predicted decline
whereas hippocampal volume and T2 midpoint did not.
Based on the presented T2 relaxometry data, we
propose the following model in Fig. 5 where healthy age-
ing is characterised by a relative dominance of factors that
increase T2 over factors that decrease T2, particularly in
the thalamus. Incipient Alzheimer’s disease may be char-
acterised by additional factors that decrease T2, balancing
out the effects of T2-increasing factors on T2 midpoint to
some extent. This leads to an increasing width of the dis-
tribution of T2 without necessarily changing the midpoint
in prodromal AD. We see this in our MCI cohort, who
are at increased risk of a later diagnosis of AD [39, 40, 50].
In later stages of disease, after a diagnosis of Alzheimer’s
disease, factors that increase T2 may predominate. This
model explains these data and ties together previous
seemingly conflicting literature such as the discrepancy
between human and animal literature of T2 changes due
to Alzheimer’s disease (see supplementary information for
full discussion on this point).
T2-prolonging factors are dominant in healthy ageing
and later stage Alzheimer’s disease
The primary causes of variability in T2 are content and
mobility of water. T2 increases as water mobility increases
[51]. The amount of free water in a region can be partially
attributed to the inverse of the compartmentalisation of
the water, as is caused by cell membrane disruption. As
cells die, whether due to normal ageing processes [16, 17]
or pathology, cell membranes become damaged, thereby
increasing the amount of free water within a tissue [52].
Fig. 3 The ability of hippocampal metrics to predict cognitive change over 1 year. Data shown are partial residual (PR) plots for hippocampal
structural measures predicting follow-up cognitive score, correcting for age and baseline cognition. Y-axes show standardised residuals from
linear regression of age and baseline cognitive score predicting follow-up cognitive score. X-axes also show standardised residuals with the same
predictors, predicting hippocampal T2 midpoint (a), T2 heterogeneity (b) or ICV-corrected volume (c). Solid black lines represent linear regression
slopes with p < .05. Dotted lines represent those with p > .05. Regression lines are shown with ± 95% confidence intervals
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The breakdown of myelinated structures also causes T2 to
increase in white matter and can be caused by both ageing
and Alzheimer’s disease [24, 53–57], as well as other con-
ditions including vascular dementia [58]. This leads to an
increase in T2 both in healthy ageing and in Alzheimer’s
disease, even in early stages, as a result of microstructural
damage. In support of this, this study shows a significantly
longer T2 in the thalamus of Alzheimer’s disease patients
compared to healthy controls, as well as in cognitively
normal older people.
Additionally, we show that T2 heterogeneity is pre-
dicted by age in both the thalamus and hippocampus, an
effect that would be expected from uneven increases in
T2 across the region. However, T2 does not appear to
increase significantly in the hippocampus either with age
or disease progression, except perhaps at later stages of
the disease course, after a diagnosis of Alzheimer’s dis-
ease. One explanation is that the increase in T2 is bal-
anced out in the hippocampus by T2-shortening factors
that are present even prior to MCI diagnosis. This is dis-
cussed further in the following sections.
T2-shortening factors may indicate pathology beyond the
effects of ageing
Dense protein structures (e.g. Aβ, NFTs) and paramag-
netic materials (e.g. iron) cause T2 to decrease due to an
increased macromolecule-to-water ratio and the restric-
tion of water motility in the extracellular space. Neuro-
pathology defined by overexpression of such factors might
therefore be expected to decrease T2 in localised regions
of deposition. In the case of Alzheimer’s pathology, this
would occur in the hippocampus and thalamus, balancing
out the T2-prolonging factors discussed previously. In
support of this, this study shows a substantial increase in
distribution width of T2 in both hippocampus and thal-
amus, after correcting for age, in people with MCI com-
pared to healthy controls. Furthermore, the study also
shows no increase of T2 midpoint in MCI compared to
controls, a result to be expected given counteracting fac-
tors increasing and decreasing T2.
The described model is further supported by a previ-
ous study by Su et al. [59]. The cross-sectional results of
their study revealed that Alzheimer’s disease patients
Fig. 4 Linear regressions for age predicting T2 model descriptive parameters in hippocampus and thalamus. Regressions shown are between age
and hippocampal T2μ (a), thalamic T2μ (b), hippocampal T2σ (c), thalamic T2σ (d), hippocampal volume (e) and thalamic volume (f). All volumes
were normalised to ICV. Solid black lines represent linear regression slopes with p < .05. Dashed lines represent those with p > .05. Regression lines
are shown with ± 95% confidence intervals
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had significantly reduced T2 compared to healthy con-
trols. However, longitudinally, T2 in Alzheimer’s disease
patients was seen to increase. The currently presented
model explains these results in terms of a shift in the
dominance of factors that increase or decrease T2
throughout the progression of Alzheimer’s disease.
Macromolecular pathological hallmarks cause T2 to de-
crease in the first instance, which later causes physical
damage to the structure, causing T2 to increase as the
disease progresses (Fig. 6), as is seen in the majority of
studies on T2 in Alzheimer’s disease [26–30].
There is, of course, considerable debate as to the role
of plaques in Alzheimer’s disease pathology (for a review
see [60]) and some question as to the disease-specificity
of iron accumulation [36, 61]. Indeed, plaques have been
found in the brains of many people without any other
sign of Alzheimer’s disease, particularly in the hippo-
campus [62, 63]. Oligomeric Aβ, however, could still
have T2-shortening effects in the brains of people with
early Alzheimer’s disease. The presence of some T2-
shortening factors even in those with no Alzheimer’s
disease-specific pathology could explain the lack of cor-
relation between hippocampal T2 midpoint and age in
healthy control participants. In further support of this,
we do see a strong correlation between T2 midpoint and
age in the thalamus, a region which is less likely to
display pathology in a healthy control cohort [14, 63].
This is discussed further in supplementary information.
T2-shortening could also be caused by iron in microglia
which are recruited in response to inflammation. Al-
though inflammation is a factor in Alzheimer’s disease,
Fig. 5 Schematic diagram of T2 distribution profiles in ageing and Alzheimer’s disease. Midpoint values for each hypothetical distribution are
represented by orange bars and ‘μ’ markers on each x-axis. Green and red arrows represent factors that increase or decrease T2, respectively. The
number of arrows represents the relative dominance of each effect. In summary, the model suggests that factors that increase T2 are present in
both healthy ageing and Alzheimer’s pathology; however, factors that decrease T2 are more dominant in Alzheimer’s disease. Early Alzheimer’s
disease pathology is characterised by an increase the distribution without an increase in the midpoint
Fig. 6 Theoretical model of T2 dynamics in a single voxel in the
brain throughout the course of Alzheimer’s disease. A given region
in the brain of someone with incipient Alzheimer’s disease would
consist of many voxels at different stages of this curve, depending
on the degree of Alzheimer’s pathology in a given location. This
heterogeneity is what will cause the average or midpoint T2 to
remain relatively static, and the distribution width to increase, until
very late stages when all voxels reach the ‘high T2’ state
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it could also be present in response to comorbidities like
cardiovascular disease [64]. Conversely, cardiovascular
disease could also reduce blood flow to the brain, poten-
tially reducing the iron and causing T2 to increase. Un-
fortunately, amyloid and iron status of the current
studies’ participants were not available, so the higher
number of voxels with low T2 cannot be directly attrib-
uted to either factor. Future work could aim to coloca-
lise areas of low T2 with Aβ, for example with positron
emission tomography (PET), and brain iron levels by
measuring field dependent relaxation rate increase
(FDRI) as was conducted by Raven et al. [65].
Despite some presence of Aβ and iron in healthy age-
ing, various studies suggest that the two factors combine
in Alzheimer’s pathology, leading to the much greater
T2-shortening effects seen in Alzheimer’s disease. A
study by El Tannir El Tayara et al. [23] showed that T2
in the hippocampus (specifically in the subiculum) was
decreased in a mouse model of Alzheimer’s disease that
produced amyloid deposits (APP/PS1), compared to an-
other model that does not form such deposits (PS1).
The authors attribute this, at least in part, to the coloca-
lization of amyloid and iron. Such histological colocali-
zation has also been reported by Falangola et al. [66].
Excess iron can not only contribute to oxidative stress in
and of itself, but can also contribute to Aβ and NFT
misfolding [67], thereby exacerbating Alzheimer’s path-
ology. Numerous studies are supportive of the idea that
a combination of iron and Aβ cause significant T2 short-
ening [23, 35, 66, 68–73]. This also has implications for
Lewy body diseases such as Parkinson’s disease, which is
also characterised by increased iron deposition [36].
Potential clinical utility of T2 relaxometry
Understanding T2 dynamics in preclinical Alzheimer’s
disease and healthy ageing offers the potential for great
clinical benefit. If Alzheimer’s pathology can be detected
using MRI prior to the onset of hippocampal atrophy,
significant change in cognition, or loss of daily inde-
pendence, patients may receive treatment much earl-
ier—at a stage where neurodegenerative damage is
preventable or even reversible. Additionally, as our pilot
data show [25], T2 heterogeneity outperforms more
traditional measures of microstructural integrity in the
identifying pathology.
In this study, we show that T2 heterogeneity can pre-
dict cognitive decline in the MCI group where volume
and T2 midpoint cannot. This effect was significant after
regressing out the effect of age suggesting that it does
relate to pathology or other age-independent brain
changes. Furthermore, any test-retest variability in the
cognitive tests used would likely only introduce noise ra-
ther than systematic bias. We therefore believe this re-
sult to be robust.
Hippocampal volume is the one of the most widely
studied and effective predictors of cognitive decline (for
a review, see de Flores et al. [74]). However, rather than
measuring pathology itself, volumetry measures tissue
atrophy, a consequence of pathology. T2 increases also
measure consequences of pathology, in the form of in-
creased regional CSF, oedema or cell membrane break-
down; however, it is a more sensitive measure and may
indicate subtle damage before macroscopic atrophy is
detectable. Furthermore, T2 decreases may measure key
features of Alzheimer’s pathology itself, such as iron, Aβ
and NFT deposition that can occur before hippocampal
shrinkage [75]. Measuring T2 heterogeneity allows these
opposing factors to be considered, as they may indicate
slightly damaged tissue that has the potential for thera-
peutic rescue. Measuring T2 distribution width com-
pared to age-corrected normative data may be indicative
of physical damage beyond what should be expected for
a given age. Given systematic differences in T2 between
pulse sequences (as seen in Supplementary Tables 1–4),
exact normative data would have to be standardised for
a given sequence. However, as we see consistent results
across two cohorts with two different pulse sequences,
we expect these results to be highly generalisable across
sequences. These markers may compliment or even sur-
pass volumetry in predicting future cognitive decline. As
neuroimaging, often MRI, is part of routine clinical
screening processes for neurological disease, this method
is highly practical and easily translatable.
It is important to highlight that even though our re-
sults are largely discussed in the context of AD, an in-
crease in the distribution of T2 is likely not specific to
AD per se, but rather may be a highly versatile novel
measure of microstructural integrity that can be applied
to the diagnosis of many diseases. It is likely to be par-
ticularly useful in any disease characterised by factors
which both increase and decrease T2, in which changes
in T2 midpoint would be masked. This may include
many neurodegenerative disorders, particularly those
where age is a risk factor, such as dementia with Lewy
bodies, Parkinson’s disease or vascular dementia. MCI is
also a risk factor for these disorders [76, 77], and path-
ology for these conditions is likely present within our
MCI population. As with any structural measure, it will
be the spatial and temporal patterns of microstructural
changes throughout the brain which may be specific to a
given disease. This study focused on the MTL and thal-
amus in groups with high risk of AD pathology, thus dis-
cussion centres mostly around AD. However, non-AD
disease pathology may also be present in our MCI co-
hort also causing increased T2 heterogeneity in the
hippocampus and/or thalamus.
With further research to characterise the pattern of
microstructural changes in T2 distribution and volume
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within the brain, perhaps by looking in closer detail at
subfields of the MTL, T2 heterogeneity may be used to
develop more specific diagnostic criteria early on in the
disease process. If this is the case, MRI may become a
non-invasive alternative to CSF biomarker analysis and a
cheaper option than amyloid or tau PET scanning, both
of which can detect very early AD pathology [78, 79].
Furthermore, although CSF biomarkers provide a good
overview of the presence of pathology, T2 heterogeneity
allows direct quantification of tissue which, although
damaged, may stand a chance of therapeutic rescue, and
may therefore predict treatment efficacy on a patient by
patient basis. The combined value of T2 heterogeneity
and CSF biomarkers is, of course, an exciting avenue for
future research.
In addition to the clinical utility of T2 heterogeneity
described here, T2 heterogeneity also has potential for
use in basic and translational research. Current studies
of the function of human hippocampus and its constitu-
ent subfields, for example, often involve assessing rela-
tionships with volume, despite limitations of the ‘bigger
is better’ hypothesis (see review by Petten [80]). T2 het-
erogeneity may be used to identify tissue that is extant
but dysfunctional, which may otherwise confound volu-
metry, leading to more accurate assessment of the
amount of ‘healthy’ tissue present. This, of course, has
the potential for application to other brain areas and
may contribute to an overall better understanding of
brain-behaviour relationships in health and disease.
Limitations
With the exception of some of those who have actually
received a clinical diagnosis of Alzheimer’s disease in
study 1, the amyloid status of these participants is un-
known. Amyloid (measured either in CSF or using PET)
is one of the most commonly used biomarkers to in-
crease certainty of the presence of Alzheimer’s disease
pathology. Those who present with mild cognitive
impairment often are only classified as MCI based on
presentation of cognitive symptoms. Such cognitive
impairment could be caused by factors other than
Alzheimer’s pathology, including other dementias,
stroke, pharmaceutical side effects and sleep problems to
name a few. Further work is required to understand the
ability of T2 heterogeneity to rule out causes of MCI not
related to dementia.
Secondly, although we present results in a relatively
large sample of healthy older controls and people with
MCI, we are limited by our small sample of Alzheimer’s
disease patients. This is primarily because they were only
recruited as a part of study 1. This limits the statistical
significance of some of the effects that we describe, and
therefore conclusions from this group are slightly tenta-
tive. This is acknowledged throughout interpretation of
these results, which we expect to be reproducible with a
larger sample size. The lack of any observed statistical
difference between MCI and AD groups is also further
discussed in supplementary information.
Thirdly, this study combines two distinct participant
cohorts, the methodology of which differ in two key
ways: (i) the test used to measure general cognitive abil-
ity (study 1: MoCA; study 2: ACE-III) and (ii) the MRI
sequence used to quantitatively assess T2 (study 1: 10-
echo CPMG; study 2: 3-echo TSE). For these data, we
have normalised within-cohort (calculated Z scores) and
combined data after normalisation. Given that the co-
horts are similar in almost every other way, and these
methods are purported to measure the same underlying
principles, the benefits of a larger sample size provide
ample justification for combining cohorts as we have
done.
Finally, the only regions studied here, hippocampus
and thalamus, are both regions known to be affected by
Alzheimer’s pathology at early stages. Future studies
would benefit from exploring T2 dynamics in other
brain regions, including those that are not directly impli-
cated in early Alzheimer’s disease. This is not possible
with existing data for either study 1 or study 2, as the
multi-echo T2 scans acquired do not cover the whole
brain. Future analyses should also focus on subdivisions
in these regions, such as T2 differences between MTL
subfields and across individual thalamic nuclei, which
have different susceptibility to AD pathology.
Conclusions
In this paper, we show that T2 heterogeneity is a good
measure of microstructural integrity of brain tissue. We
propose a model (Fig. 5) that suggests factors that in-
crease T2 are indicative of microstructural damage but
are not necessarily specific signs of Alzheimer’s path-
ology. Rather, factors that decrease T2 are prevalent in
Alzheimer’s pathology and may occur in the earliest
stages of disease (Fig. 6). These two opposing forces act
to balance out the mean in prodromal Alzheimer’s dis-
ease, causing varied results in the human literature. The
model makes specific and testable predictions about the
temporal dynamics of T2 alterations throughout ageing
and prodromal Alzheimer’s disease. It also highlights po-
tential early indicators of Alzheimer’s disease, allowing
Alzheimer’s disease-related cognitive decline to be dis-
tinguished from that seen in healthy ageing. We show
that T2 heterogeneity surpasses midpoint T2 and the
more established measure of volumetry in predicting
cognitive decline in those with MCI.
This study represents one of the first studies of T2
heterogeneity within the brain in MCI and Alzheimer’s
disease, and the first to show its utility in predicting cog-
nitive decline.
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